Charles Sigal

Charles Sigal

Director/Board Member chez VIR BIOTECHNOLOGY, INC.

Fortune : 656 989 $ au 31/03/2024

72 ans
Health Technology
Commercial Services
Health Services

Profil

Charles Elliott Sigal is currently serving as a Director at Medarex, Inc. He is also an Independent Director at Alnylam Pharmaceuticals, Inc., Vir Biotechnology, Inc., Affinia Therapeutics, Inc., and Tessera Therapeutics, Inc. Additionally, he holds positions as a Member of the Drug Discovery & Development Forum at the National Academy of Medicine (United States) and a Member of the President Council at The J.
David Gladstone Institutes.
Dr. Sigal is a Trustee at University Medical Center and manages Segal Family Investments LLC.
In his former roles, Dr. Sigal served as the Chief Executive Officer and Vice President of R&D at Mercator Genetics, Inc. He was also the Director, Chief Scientific Officer, and Executive VP at Bristol Myers Squibb Co. from 2011 to 2013.
Additionally, he held the position of Director at Mead Johnson Nutrition Co. from 2012 to 2017.
Dr. Sigal served as an Independent Director at Spark Therapeutics, Inc. from 2014 to 2019 and as an Independent Non-Executive Director at Surface Oncology, Inc. from 2018 to 2023.
He also served as an Independent Non-Executive Director at Adaptimmune Therapeutics Plc from 2015 to 2023.
Furthermore, Dr. Sigal was a Non-Executive Director at Adaptimmune Ltd.Dr. Sigal obtained his doctorate degree from The University of Chicago in 1981.
He pursued his graduate studies at Purdue University and completed his undergraduate and second doctorate degrees there in 1973 and 1977, respectively.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
31/01/2024 2 000 ( 0,00% ) 298 900 $ 31/03/2024
22/05/2023 25 806 ( 0,02% ) 261 415 $ 31/03/2024
03/07/2023 367 038 ( 0,06% ) 96 674 $ 31/03/2024

Postes actifs de Charles Sigal

SociétésPosteDébut
VIR BIOTECHNOLOGY, INC. Director/Board Member 02/07/2020
ALNYLAM PHARMACEUTICALS, INC. Director/Board Member 22/08/2022
Melanoma Research Alliance Director/Board Member 01/11/2013
Director/Board Member 15/06/2021
Director/Board Member 08/06/2020
Segal Family Investments LLC Corporate Officer/Principal -
Corporate Officer/Principal -
Corporate Officer/Principal -
Director/Board Member -
░░░░░░░░░░ ░░░░░░░ ░░░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
Tous les postes actifs de Charles Sigal

Anciens postes connus de Charles Sigal

SociétésPosteFin
░░░░░░░░░░░ ░░░░░░░░░░░░ ░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░░░ ░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░ ░░░░░░░ ░░░░░░░░░ ░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░ ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░
Voir l'expérience en détail de Charles Sigal

Formation de Charles Sigal

The University of Chicago Doctorate Degree
Purdue University Graduate Degree

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Charles Sigal

Relations

98

Relations au 1er degré

20

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Sociétés cotées4
BRISTOL-MYERS SQUIBB COMPANY

Health Technology

ALNYLAM PHARMACEUTICALS, INC.

Health Technology

VIR BIOTECHNOLOGY, INC.

Health Technology

ADAPTIMMUNE THERAPEUTICS PLC

Health Technology

Entreprise privées14

Commercial Services

Consumer Non-Durables

Commercial Services

Health Services

Commercial Services

Commercial Services

Health Services

Health Services

Health Technology

Melanoma Research Alliance

Miscellaneous

Health Technology

Health Technology

Health Technology

Segal Family Investments LLC

Voir les connexions sociétés
  1. Bourse
  2. Insiders
  3. Charles Sigal